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ABSTRACT: {Fe[Gd2bpy(DTTA)2(H2O)4]3}
4 is a self-assembled, metallostar-structured potential MRI contrast agent, with
six efficiently relaxing Gd3þ centres confined into a small molecular space. Its proton relaxivity is particularly remarkable at
very high magnetic fields (r1¼ 15.8mM1 s1 at 200MHz, 378C, in H2O). Herewe report the first in vivoMRI feasibility study,
complemented with dynamic g scintigraphic imaging and biodistribution experiments using the 153Sm-enriched compound.
Comparative MRI studies have been performed at 4.7T in mice with the metallostar and the small molecular weight contrast
agent gadolinium(III)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate ([Gd(DOTA)(H2O)]
¼GdDOTA). The metallos-
tar was well tolerated by the animals at the concentrations of 0.0500 (high dose) and 0.0125 (low dose) mmol Gd kg1 body
weight; (BW). The signal enhancement in the inversion recovery fast low angle shot (IR FLASH) images after the high-dose
metallostar injection was considerably higher than after GdDOTA injection (0.1mmolGdkg1 BW), despite the higher dose of
the latter. The high-dose metallostar injection resulted in a greater drop in the spin-lattice relaxation time (T1), as calculated
from the inversion recovery true fast imaging with steady-state precession (IR TrueFISP) data for various tissues, than the
GdDOTA or the low dose metallostar injection. In summary, these studies have confirmed that the approximately four times
higher relaxivity measured in vitro for the metallostar is retained under in vivo conditions. The pharmacokinetics of the
metallostar was found to be similar to that of GdDOTA, involving fast renal clearance, a leakage to the extracellular space in the
muscle tissue and no leakage to the brain. As expected on the basis of its moderate molecular weight, the metallostar does not
function as a blood pool agent. The dynamic g scintigraphic studies performed in Wistar rats with the metallostar compound
having 153Sm enrichment also proved the renal elimination pathway. The biodistribution experiments are in full accordance
with the MR and scintigraphic imaging. At 15min post-injection the activity is primarily localized in the urine, while at 24 h
post-injection almost all radioactivity is cleared from tissues and organs. Copyright # 2006 John Wiley & Sons, Ltd.
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INTRODUCTION
Over the last two decades, magnetic resonance imaging
(MRI) has grown into one of the most prominent
modalities in medical diagnostics. This primarily non-
invasive technique allows high-resolution images of a
given part of the body to be obtained. The successful
history of MRI, which was awarded the 2003 Nobel Prize
for Physiology andMedicine, has been largely assisted by
the concomitant development of MRI contrast agents
(CA) (1). These drugs—GdIII complexes in the major-
ity—enhance the image contrast by accelerating the water
proton relaxation in the surrounding tissues. The efficacy
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of a contrast agent is commonly measured by its
millimolar relaxivity (r1), which is the ability of the
paramagnetic agent to enhance the longitudinal proton
relaxation rate, referred to 1mM concentration (of GdIII).
The currently marketed MRI contrast agents display
relaxivities around 4–5mM1 s1; however the Solomon–
Bloembergen–Morgan theory predicts much higher
values for GdIII complexes, provided the rotation and
electron spin relaxation are slow and the water exchange
rate between the inner sphere and the bulk solvent is
optimal (2).
Several emerging MRI applications, first of all in the
field of molecular imaging, require very high efficacy
contrast agents (3). It implies both high molar relaxivity
per GdIII and high relaxivity concentrated into a limited
molecular volume. In the perspective of developing
contrast agents that concentrate high relaxivity into a
small molecular space, we have recently started exploit-
ing heterometallic assemblies. We have reported the
synthesis (4) and physicochemical characterization (5) of
a heterotritopic, bipyridine derivative poly(amino car-
boxylate) ligand which is capable of self-assembling with
GdIII and FeII into a rigid metallostar structure
{Fe[Gd2bpy(DTTA)2(H2O)4]3}
4 (Fig. 1). This com-
pound possesses a high proton relaxivity, comparable to
that of high generation dendrimers. Several key features
contribute to the high relaxivity of the metallostar (5): (i)
the rigidity of the metallostar originating from the non-
flexible Fe(bpy)3 core; (ii) the presence of six efficiently
relaxing GdIII metals within one molecule, each bearing
two inner sphere water molecules (all commercially
available contrast agents have a single inner sphere
water); and (iii) the water exchange rate of the 12 water
molecules is close to the optimal value. Moreover, with
six GdIII ions in a relatively low molecular mass of
3744 gmol1, the metallostar is a highly powerful
contrast agent in terms of efficacy by unity mass. Indeed,
this compound represents the most concentrated para-
magnetic relaxation effect among all GdIII-based poten-
tial contrast agents ever reported (4).
Given the greater spatial resolution and sensitivity
associated with higher frequencies, the current tendency
in MRI is to increase the magnetic field. In the clinics
today, most MRI machines work at 1.5–3T. However, for
experimental animal studies, much higher fields are
commonly applied (up to 9.4 T or even higher) (3,6).
Macromolecular contrast agents often have a high proton
relaxivity peak centred between 20 and 60MHz; however,
above this frequency the longitudinal relaxivity strongly
decreases with increasing field and, at high fields,
macromolecular agents are hardly superior to small
molecular weight chelates. The Solomon–Bloembergen–
Morgan theory predicts that at frequencies above
200MHz the relaxivity increases with the inverse of
the rotational correlation time tR, in contrast to lower
frequencies, where it is proportional to tR. Consequently,
at very high fields intermediate size molecules, such as
the metallostar, are favourable over very large ones.
Indeed, the metallostar has an unusually broad high field
relaxivity peak centred at a relatively high frequency, and
exceptionally high relaxivities above 60MHz (Table 1).
This high relaxivity, which is additionally confined to a
small molecular space (high density of relaxivity), makes
the metallostar a prime candidate for high-field MRI
contrast agent applications.
Here we report the first in vivo MRI feasibility study
with the metallostar as a potential medical MRI contrast
agent. The pharmacokinetics and in vivo relaxivity were
determined in mice and compared with those of a typical
commercial, small molecular weight contrast agent,
GdDOTA. In addition, to complement the MRI results
we have performed dynamic g scintigraphic and
biodistribution studies in Wistar rats at short (10–
15min) and long (24 h) periods of time by using the
Figure 1. (a) Schematic structure and (b) molecular modeling representation of the metallostar
{Fe[Gd2bpy(DTTA)2(H2O)4]3}
4.
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153Sm analogue metallostar compound, {Fe[153Sm2bpy
(DTTA)2(H2O)4]3}
4.
EXPERIMENTAL
The synthesis of the ligand H8bpy(DTTA)2 has been
described in a previous communication (4). 153-
Samarium chloride (153SmCl3) was produced at the
ITN (Instituto Tecnolo´gico e Nuclear), Lisbon, with a
specific activity >5GBqmg1. For this purpose a
153Sm2O3 was prepared from a 98% samarium-152
enriched samarium oxide target, sealed into a quartz vial
and welded into an aluminium can, by neutron irradiation
using a thermal flux of 2.3 1013 n cm2 s1. Following
irradiation, the samplewas opened, dissolved in HCl (1 M)
and the final 153SmCl3 was brought to a stock
concentration of 1.9mM.
Sample preparation
A GdCl3 solution was prepared from Gd2O3 of 99.9%
purity (Fluka) by dissolution in excess HCl, which was
evaporated off. The concentration of the metal ion was
determined by complexometric titration with standar-
dized Na2H2EDTA solution. [Gd2bpy(DTTA)2(H2O)4]
2
was prepared by adding solid ligand to a solution of
GdCl3 in 1:2 molar ratio. The pH, measured with a
calibrated combined glass electrode, was adjusted to 7.1
by addition of known amounts of NaOH (0.1 M). A slight
ligand excess was used (3%) and the absence of free metal
was checked by the xylenol orange test.
{Fe[Gd2bpy(DTTA)2(H2O)4]3}
4 was prepared by
mixing a solution of [Gd2bpy(DTTA)2(H2O)4]
2 with a
freshly prepared solution of FeII ions [Fe(NH4)2(-
SO4)  6H2O] in 3:1 molar ratio. A slight excess of
[Gd2bpy(DTTA)2(H2O)4]
2 (3%) was used to insure
complete FeII coordination. pH was set to 7.4 by addition
of HCl (0.1 M). NaCl (0.9%) was added to avoid osmotic
pressure problems upon injection. The final concentration
of the Gd-metallostar solution was CGd¼ 10.0mM.
[Sm2bpy(DTTA)2(H2O)4]
2 was prepared by adding
an excess of solid ligand to a solution of SmCl3 (the
concentration of the metal ion was determined by
complexometric titration with standardized Na2H2EDTA
solution). A solution of 153SmCl3 was then added to the
previous solution. The final solution contained a 3%
excess ligand in respect to the overall samarium
concentration to ensure complete metal coordination.
pH was adjusted to 7.0 by addition of known amounts of
NaOH (0.1 M).
{Fe[Sm2bpy(DTTA)2(H2O)4]3}
4 was prepared by
mixing a solution of [Sm2bpy(DTTA)2(H2O)4]
2 with
a freshly prepared solution of FeII ions [Fe(NH4)2
(SO4)  6H2O] in 3:1 molar ratio. A slight excess of
[Gd2bpy(DTTA)2(H2O)4]
2 (3%) was used to ensure
complete FeII coordination. pH was set to 7.4 by addition
of known amounts of NaOH and HCl (both 0.1 M). The
final concentration of the Sm-metallostar solution was
CSm¼ 18.9mM.
MRI
MR measurements were performed on a 4.7 T Bruker
Biospec MR system (Bruker Biospin, Ettlingen, Germany)
equipped with a 12 cm bore gradient system using a
birdcage resonator with inner diameter of 35mm.
For anatomical reference, a multislice rapid acquisition
and relaxation enhancement (RARE) sequence was per-
formed with the following parameters: RARE factor¼
16, echo time (TE)¼ 10ms, repetition time (TR)¼ 2.5 s,
15 axial slices (eight coronal slices), slice thickness
1.5mm, field of view (FOV)¼ 3.3 cm 3.3 cm
(FOV¼ 4.5 cm 4.5 cm), matrix¼ 256 128.
Regional contrast agent uptake was assessed with
DCE-MRI with two different imaging methods:
(1) A series of IR FLASH images (7) was acquired using
the following parameters: flip angle a¼ 128,
TE¼ 3.0ms, TR¼ 6.9ms, 1 slice, slice thick-
ness¼ 1.5mm, matrix¼ 128 96, inversion delay
0.9 s, 256 repetitions with temporal resolution 6 s,
duration 25min. The imaging slice was either axial
with FOV¼ 4.1 cm 4.1 cm, or coronal oblique with
FOV¼ 4.5 cm 4.5 cm. CA was injected at repeti-
tion 8 (see below). Before the start of the DCE-MR
image series, a reference imagewas acquired with the
same sequence parameters but without the inversion
pulse.
(2) A series of IR TrueFISP images (8) was acquired
using following parameters: flip angle a¼ 308,
TE¼ 1.69ms, TR¼ 3.38ms, range of inversion time
(TI)¼ 210–2480ms, 1 axial slice, slice thick-
ness¼ 2.0mm, FOV 30mm 22.5mm. Matrix was
64 48, TI increment (i.e. acquisition time for one
frame) was 162ms, number of frames was 16. The IR
TrueFISP block was repeated 80 times. The temporal
resolution (i.e. time period between the start of two
successive image blocks) was 10 s before CA injec-
tion at repetition 8, and 8 s thereafter. The overall
experimental duration was 12min.
Table 1. High-field proton molar relaxivities, r1 (mM
1
s1), for GdDOTA and the metallostar measured in
water
200MHz 400MHz
(4.7 T) (9.4 T)
258C 378C 258C 37 8C
Metallostar 16.4 15.8 9.3 8.5
GdDOTA 4.0 3.0 3.9 3.0
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AllMRI studies were performed in strict adherence to the
Swiss law for animal protection. In vivo experiments were
performed in female C57/BL6 mice (n¼ 8, 20–25 g,
obtained from Charles River Laboratories France). The
group sizes were n¼ 3 for the IR FLASH experiments
and n¼ 5 mice for the IR TrueFISP experiments. The mice
were anaesthetized with isoflurane (1.5–2.5%) in an O2–
N2O 1:2 mixture applied with a face mask allowing free
breathing. The temperature was kept at 388C with a current
of warm air, and the respiration was monitored (using a
balloon taped to the abdomen and connected to a pressure
transducer). In three animals respiration rate, heart rate (with
electrocardiogram electrodes attached to the front paws),
and body temperature (with an intrarectal temperature
probe) were recorded during the experiment with GdDOTA
and metallostar injection with two different doses, respec-
tively. The metallostar was injected as a bolus via a tail vein
catheter with an infusion pump (3mlmin1) at a dose of
0.05mmolGdkg1 body weight (BW) (high dose) or
0.0125mmolGdkg1 BW (low dose), i.e. 5 or 1.25ml g1
1 BWof the CA solution were injected. For comparison, the
experiments were repeated in the same mice with injection
of the clinically approved small molecular weight CA
GdDOTA (Dotarem, Guerbet, France). A dose of
Figure 2. IR FLASH images taken at different times of the DCE-MRI experiment in mice. Rows
1 and 2 represent the high-dose metallostar (0.05mmolGd kg1 BW) injection, whereas rows
3 and 4 represent the GdDOTA (0.1mmolGd kg1 BW) injection. Rows 1 and 3 show axial
slices, and rows 2 and 4 coronal slices. The first images of rows 1 and 2 are anatomical RARE
images.
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0.1mmolGdkg1 BW was injected via a tail vein catheter,
corresponding to 0.2ml g1 BW CA solution.
MRI data processing
CA concentration was calculated from the change in
signal intensity S(t) in the DCE-MRI series with software
tools developed in-house with the IDL 6.1 programming
environment (Research Systems Inc., Boulder, CO,
USA). T1 maps were calculated for each time point on
a pixel-by-pixel basis from each image using the standard
IR equation (9) for the IR FLASH images,
T1 ¼ TI
ln 0:5 1 S
S0
   (1)
where TI is the inversion time and S0 is the signal intensity
in the pre-contrast reference image.
For the IR TrueFISP images, a three-parameter fit of
the signal time course S(t) over the eight image frames
(with different inversion delays t) was performed using
the following model function (10):
S tð Þ ¼ Sstst 1 INV  eðt=T1Þ
h i
(2)
where T1
 is the apparent relaxation time, Sstst the steady
state signal, and INV the inversion factor (i.e. the ratio
between the absolute signals at TI¼ 0 and Sstst). T1 was
computed using a least-square fitting routine.
T1 was calculated for each time point from the
following equation (10):
T1 ¼ T1 cos
a
2
INV  1ð Þ (3)
where a is the excitation flip angle.
Apparent Gd concentrations, CGd, were then
calculated (for both IR FLASH and IR TrueFISP
experiments) for each time point with the following
formula:
CGd ¼ ð1=T1Þ  ð1=T10Þ
r1
(4)
using the molar relaxivities r1 of 13.5 s
1mM1 per Gd for
the metallostar (measured in saline at 4.7 Tand 378C) and
3.3 s1mM1 for GdDOTA [measured in water with 4%
human serum albumin (HSA) at 4.7 T and 378C; personal
communication, Guerbet]. T10 was the mean baseline T1,
i.e. the mean of the first seven scans.
Mean gadolinium concentration time courses C(t) were
calculated in several regions of interests (ROIs): skeletal
muscle, kidney cortex and medulla, brain, liver and blood
pool in the jugular vein.
Biodistribution and g imaging
A g camera-computer system (GE 400 GenieAcq, from
General Electric, Milwaukee, USA) was used for
acquisition and pre-processing. Data processing and
display were performed on a personal computer using a
homemade software developed for the IDL 5.2 computer
tool. Awell counter (DPC-Gamma C12, LA, USA) with a
Compaq DeskPro compatible computer was used for
activity counting in the biodistribution studies.
g–Images were obtained and biological distribution of
the 153Sm-metallostar complex was determined using
200 g Wistar rats (used as groups of four; provided by
Charles River Laboratory Barcelona, Spain). All animal
studies were carried out in compliance with procedures
approved by the appropriate institutional review commit-
tees. Conscious rats were allowed free access of food and
water ad libitum. Four animals were anaesthetized with
ketamine (50mgml1)–chloropromazine (2.5%) (10:3)
and injected in the femoral vein with ca. 200mCi of
153Sm-metallostar. The animals were then positioned in
ventral decubitus over the detector. Image acquisition was
initiated immediately before radiotracer injection.
Sequences of 120 images (of 5 s each) were acquired
to 64 64 matrices. Images were subsequently processed
using an IDL-based program. In order to analyze the
transport of radiotracer over time, four ROI were drawn
on the image files, corresponding to the thorax, liver, left
kidney and bladder. The time–activity curves were
obtained from these regions. Animals were sacrificed
15min after injection and the major organs removed were
weighed and counted in a g well-counter. Similar
biodistribution studies with a group of four rats sacrificed
24 h after i.v. injection of 153Sm-metallostar were also
performed.
RESULTS AND DISCUSSION
Magnetic resonance imaging
Effect of the metallostar on vital functions. The
CAwas well tolerated by the mice. No gross side effects
were observed during injection, immediately or days after
the experiment. In the high-dose metallostar experiments
(0.05mmolGd kg1 BW), a drop in the respiration
frequency of approximately 25% (from 28 to 19 bpm) and
a drop in the heart rate of approximately 10% (from 450 to
405 bpm) were observed in the first minute post-injection.
Five minutes post injection, the values returned to the pre-
injection level. No such drop was observed after
GdDOTA or the lower dose metallostar injection. After
all three types of injection, the body temperature slightly
increased (approximately 0.28C). Overall, the metallostar
seemed to be harmless to the animals; however, a more in-
depth study should be performed to further assess its
toxicology.
DCE-MRI in vivo. Comparison between the
metallostar and GdDOTA. IR FLASH images of
the dynamic contrast enhanced MRI (DCE-MRI)
Copyright # 2006 John Wiley & Sons, Ltd. Contrast Med. Mol. Imaging 1: 30–39 (2006)
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experiment with the metallostar (high dose; 0.05mmol-
Gd kg1 BW) and GdDOTA (0.1mmolGd kg1 BW) are
displayed in Fig. 2. In the pre-injection image, the vena
cava, kidneys and muscle were dark due to the particular
inversion delay chosen. After injection, the kidneys and
vena cava were lit up as a result of T1 shortening. A slight
enhancement in the paravertebral muscle and liver was
also observed for both CAs.
The signal intensity time courses of the IR FLASH
images are displayed in Fig. 3 (top). The scattering in the
curves was caused by animal motion. Despite its lower
dose, the metallostar resulted in a considerably higher
signal enhancement as compared with GdDOTA (the
sameMRImethod and acquisition parameters were used).
This finding is in full accordance with the remarkably
higher in vivo relaxivity of the metallostar compared to
GdDOTA (see below).
The gadolinium concentration time courses, C(t), were
calculated from the IR FLASHdata and are shown in Fig. 3
(bottom). In the different tissues, the Gd concentration was
found to be approximately twice as high for GdDOTA than
for the metallostar (high dose). This is in accordance with
the double injected dose of GdDOTA as compared with the
metallostar. For both CAs, an enrichment of Gd was
observed after 4–5min in the kidney medulla.
The T1 time courses calculated from the IR TrueFISP
data are shown in Fig. 4. Baseline T1 values (before
injection) varied slightly between individuals. The T1
drop after the high-dose metallostar injection (0.05mmol
Gd kg1 BW) was larger than the drop after GdDOTA
injection and also, as expected, larger than for the low-
dose metallostar (0.0125mmolGd kg1 BW). These
results confirm again the higher relaxivity of the
metallostar. C(t) curves calculated from these data are
also displayed in Fig. 4. In several types of tissues, the Gd
concentration was 2–4 times lower for the low dose
(0.0125mmolGd kg1 BW) as compared with the high
dose (0.05mmolGd kg1 BW) of the metallostar.
Theoretically a factor of 4 was to be expected for all
tissue types. Comparing the high-dose metallostar and the
GdDOTA data, a factor of approximately 2 between the
Gd concentrations was found in brain and muscle, while
the ratio was smaller in the kidney cortex.
Pharmacokinetics. The time course of biodistribution,
based on the observation of the CA uptake in the different
ROIs, was found to be similar for the metallostar and
GdDOTA (Fig. 3). Both CAs are primarily eliminated by
the kidneys from the blood stream, as indicated by the
high Gd accumulation in the kidney medulla. The data
Figure 3. Top row: time course of signal intensity (up to 12min post injection) in several regions of interest during IR
FLASH DCE-MRI experiments in mice with the (a) metallostar (dose 0.05mmolGd kg1 BW) and (b) GdDOTA (dose
0.1mmolGd kg1 BW). Bottom row: time course of Gd concentration (up to 12min post-injection) calculated from the
DCE-MRI data for (c) metallostar and (d) GdDOTA. The time courses are data from individual animals.
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obtained here are in accordance with previous reports on
the pharmacokinetics of GdDOTA (11) or other small
molecular weight Gd-based contrast agents (12).
For both CAs, the signal and concentration curves in
the liver revealed a steady decrease to a low plateau value
after the initial steep rise. This points to a small retention
of both CA in the liver, as expected given their relatively
small molecular weight.
Both CAs present limited T1 changes and derived Gd
concentration in the brain, as compared with kidney and
liver (Fig. 4). This reflects the lower blood volume in the
brain compared with kidney and liver and the action of the
blood–brain barrier. The shape of the curve—a steep rise
immediately after CA injection and slow decay
thereafter—indicates that there is no leakage to the brain
parenchyma due to the intact blood—brain barrier. A
different time course was observed in the muscle: the
maximum was reached 2–3min after injection. This can
be rationalized in terms of a leakage of the CA to the
extracellular space in the muscle tissue. The Gd
concentration time courses in muscle indicated that,
similarly to GdDOTA, the metallostar is not a blood pool
agent due to the relatively small size of the molecule.
Gd concentration in the blood pool could not be
calculated correctly with the IR FLASH method.
Immediately after CA injection, very high CA concen-
trations occur in the blood vessels and in the kidney. At
such high local concentrations T2 is shortened by the CA,
leading to a signal reduction. This effect was not
corrected in the IR FLASH method, which yielded too
Figure 4. Top row: time course of T1 (up to 10min post-injection) in several regions of interest during IR TrueFISP DCE-
MRI experiments with the (a) metallostar and (b) GdDOTA in mice. Bottom row: time course of Gd concentration
calculated from the previous data for the (c) metallostar (with enlarged insert) and (d) GdDOTA. High (low) dose of
metallostar was 0.05 (0.0125) mmol Gd kg1 BW. Dose of GdDOTA was 0.1mmolGd kg1 BW. The time courses are
data from individual animals.
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low T1 values and thus Gd concentration in blood and—in
some cases—also in the kidney. Therefore, the experi-
ments were also performed with the IR TrueFISP method
which is in this respect superior to the IR FLASHmethod:
(1) T2 effects are taken into account because the method
also yields T2; (2) it has a higher accuracy for T1
determination than the IR FLASH method since 16
inversion delays are included instead of just one.
The time course C(t) of the mean blood Gd
concentration could then be successfully assessed for
the lower metallostar dose (0.0125mmolGd kg1 BW) in
the jugular veins in the neck. The average of three veins in
two animals is shown in Fig. 5. During the first 2min post
injection, the Gd concentration decreased rapidly,
followed by a slower decay.
Based on the injected dose of 0.0125mmolGd kg1
BW and a blood volume of 1.5ml for a mouse with 20 g
BW, the theoretical Gd concentration in blood is 0.17mM.
Initial (8 s post-injection) Gd concentration derived in the
jugular veins for this metallostar dose was approximately
0.12mM. The close agreement between the theoretical
and experimental values reveals that the in vivo relaxivity
of the metallostar is very close to the value of
13.5 s1mM1 measured in saline.
Biodistribution and dynamic scintigraphic
studies
To complement the MRI data, biodistribution and
dynamic g scintigraphic studies were performed in
Wistar rats using a metallostar solution where the
gadolinium was replaced by a mixture of radioactive
and non-radioactive samarium (13,14). The scintigraphic
image obtained 200 s after tracer injection of 153Sm-
metallostar is shown in Fig. 6. The results are in
agreement with the MRI observations, i.e. the main
activity is found to be located in the kidneys and bladder,
which is the excretion pathway for this small and
hydrophilic complex. In addition, a very rapid clearance
from all other organs is also proved. The time–activity
curves for the 153Sm-metallostar, obtained from the
dynamic acquisition experiments, are shown in Fig. 7.
The curves were smoothed and normalized in relation to
the maximum activity obtained. Once again it is possible
to observe that the metallostar undergoes an early
clearance by the kidneys. The liver–spleen curve is
similar to the thorax curve, corresponding only to blood
activity. The fast blood elimination of the metallostar is
indicative of its stability in terms of decomplexation and
Gd release. Indeed, slower blood clearance is observed for
less stable GdIII complexes, due to reactions occurring in
serum and leading to the dissociation of the chelate (11).
The characteristics of renal clearance and rapid
washout of 153Sm-metallostar were further investigated
by biodistribution studies in Wistar rats. The results
obtained at 15min post-injection are summarized in
Fig. 8. The highest activity was found to be present in the
urine (% ID g1 in urine 7.3 4.2), which supports the
MRI and scintigraphic results obtained. It is noteworthy
that the urine had a red colour, characteristic of the
Fe(bpy)3 complex. It indicates that the Fe(bpy)3 core of
the metallostar structure remains intact even under in vivo
conditions (although this was not quantified). Biodis-
tribution was also carried out at 24 h (data not shown).
These results show that almost all the radioactivity was
cleared from tissues and organs. Only very slight
deposition (less than 0.01 %) in the bone and liver/
spleen could be observed and may be related to a very
small degree of samarium decomplexation (15,16).
Figure 5. Time course C(t) of mean blood Gd concentration
(up to 10min post-injection) measured in the jugular vein
(n¼3, mean SD) calculated from IR TrueFISP DCE-MRI
data with the metallostar (0.0125mmolGd kg1 BW).
Figure 6. Scintigraphic dynamic image obtained 200 sec-
onds after injection of 153Sm-metallostar i.v. in a Wistar rat.
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The biodistribution shows as well that the metallostar
does not cross the blood–brain barrier, as predicted by
MRI and as expected for non-lipophilic complexes.
CONCLUSIONS
MRI studies conducted at 4.7 T in mice have confirmed
that the metallostar displays approximately four times
higher in vivo relaxivity than the commercially available
GdDOTA. Furthermore, it was possible to determine that
the metallostar has similar pharmacokinetics to that of
GdDOTA, both contrast agents being eliminated from the
blood stream by the kidneys in mice. Dynamic scinti-
graphic studies performed on a metallostar with 153Sm
enrichment confirm this elimination pathway in rats.
Biodistribution experiments done in different periods of
time (15min and 24 h) proved to be in agreement with the
scintigraphic and MRI results. As expected, the activity is
overwhelmingly localized in the urine that still presents
the characteristic red color of the metallostar solution thus
attesting the stability of the metallostar.
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